Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.

摘要

Fatigue is one of the most common symptoms in multiple sclerosis (MS) and can result in severe impairment of quality of life 1. Fatigue is likely multidimensional but subtle central inflammatory activity may play a role 2, Disease modifying treatment with interferon-(3 (IFN) and glatiramer acetate (GA) successfully reduces inflammatory disease activity but does not appear to reduce levels of fatigue 3, Natalizumab (NTZ) - a monoclonal antibody against Very-Late-Activation-Antigen 4 - reduces leukocyte migration across the blood-brain barrier and thereby unfolds strong effects on central inflammation (i.e. contrast enhancing lesions or new lesions on MRI) 4, The objective of this study was to compare prevalence and severity of MS-associated fatigue in patients treated with NTZ in comparison to IFN and GA.